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ABSTRACT
Human papillomavirus (HPV) causes about 5% of all human cancers. The
HPV oncoproteins E6/E7 are responsible for the transforming potential of the virus.
Although continuous expression of the HPV oncogenes was considered
indispensable for HPV-induced carcinogenesis, we and others have demonstrated
that in a subset of HPV-positive head and neck and cervical cancers, the HPV
oncogenes are not expressed (HPV-inactive cancers). Based on the observation
that primary HPV-positive tumors express E6/E7, while metastases tend to be
HPV-inactive, we hypothesized that HPV-inactive cancers begin as HPV-active
lesions and lose their dependence on continuous E6/E7 expression during
progression. This may be due to genetic and/or epigenetic modifications caused
by the genomic instability and the additional carcinogens to which the tumor is
exposed. We observed that HPV-inactive cancers of the cervix often have mutated
p53, while HPV-active cancers do not. Therefore, we proposed that HPV positive
tumors may become inactive if p53 becomes mutated. The CRISPR-Cas9 system
was used to knock-out the p53 gene in differentiation-resistant HPV16
immortalized human keratinocytes (HKc-DR). The DNA deletions within the p53
gene were confirmed by PCR and gel electrophoresis and further validated by
Sanger sequencing. Using qPCR, we found that HPV16 E7 expression was
significantly lower (5-fold) in the p53-knocked out (KO) lines than in the p53-wild
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type (WT) lines. Reduced E7 expression in p53-KO lines was reversed by using
the demethylating agent 5-Aza-2’-deoxycytidine, suggesting that DNA methylation
plays a role in this process. Also, we used in situ hybridization to detect HPV16 E7
mRNA in p53-WT and KO lines grown as spheroids on an agarose cushion.
Interestingly, while all p53-WT lines have a uniform distribution of E7 signal, the
p53-KO lines showed some spheroids that were completely lacking E7 mRNA, and
some had a mixed population of E7-positive and E7-negative cells. These results
indicate that the p53-KO lines are a heterogeneous population in regard to HPV16
E7 expression. We concluded that p53 loss-of-function mutation may be an
important factor in driving HPV16 transformed cells to lose dependence on the
continuous expression of the HPV oncogenes and become HPV-inactive.
However, complete loss of p53 alone is not sufficient to suppress E7 expression
entirely. We also determined that loss of E7 expression may be due, at least in
part, to DNA methylation. We are currently examining HPV URR methylation in the
p53-WT and KO lines, and isolating pure lines with complete loss of HPV16 E7
expression for further studies of the molecular mechanisms that may lead to the
HPV-inactive phenotype.
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CHAPTER 1: INTRODUCTION
1.1 Human papillomaviruses (HPVs):
Human papillomavirus is a small non-enveloped virus of about 50-60 nm in
diameter. The virus has an icosahedral capsid and a circular double-stranded DNA
genome of about 8000 base pairs [1]. HPV belongs to the Papillomaviridae family.
More than 200 types of HPV can infect humans and the remaining types have been
found in other animals [2,3]. HPV types have a predilection to infect cutaneous
tissues and some of them can infect mucosal tissues, too [3].
According to the severity of the underlying conditions caused by these
viruses, HPVs have been classified into low risk (LR) and high risk (HR) types. The
LR types, like HPV types 6 and 11, have been associated with non-malignant
conditions like skin and genital warts; respiratory papillomatosis; or other noncancerous lesions. The HR types, like types 16 and 18, are found to be linked to
cancer development especially cancers of the cervix and other anogenital as well
as head and neck regions [3].
1.2 HPV life cycle:
HPV is considered the most common sexually transmitted virus, and sexual
contact is the most frequent route of transmission [4]. The location of the HPVassociated cancers may be related to the type of sexual activity. Oral sexual
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contact pattern may increase the risk of developing HPV-positive head and neck
cancer (HNC). A similar correlation can be proposed for cervical and other
anogenital cancers. Increasing the sexual activity; starting sexual life at early age;
and/or having multiple sexual partners all are factors that increase the risk of
getting infected. However, transmission from infected mother to fetus/baby during
pregnancy/delivery or through lactation has also been documented but the risk and
the frequency are much lower than the sexual route [5,6].
HPV has a tropism to infect epithelial tissue with preference to the stratified
epithelium. The multilayer architecture and the polarity of the tissue are essential
components of the viral productive life cycle [Reviewed in 7]. Infection is usually
acquired through micro-wounds in the epithelium with a predilection to infect the
basal layer as it keeps a low rate of divisions and this will help the virus escape the
immune surveillance and to produce long term infection [Reviewed in 8]. HPV
binds to heparan sulfate proteoglycans found in the cell membrane [9,10]. This will
be followed by conformational alterations in the capsid protein to deliver the virus
into the cell then introducing its genome into the nucleus [11]. Unlike other viral
infections whose viral amplification occurs in the same infected cell, HPV infects
cells of the basal layer, but its amplification occurs in the suprabasal layer
depending on host cell DNA synthesis to produce its progeny [12]. HPV
reprograms the suprabasal differentiated cells to re-enter the S phase of the cell
cycle to keep it under proliferation then the new virions shed from the epithelial
surface [3,13]. This process is called the productive life cycle of the virus where its
genome is maintained as extrachromosomal episome rather than integrating into

2

the host cell genome and it is responsible for the development of non-cancerous
lesions [14,15] (figure 1.1).
However, sometimes HPV especially the HR types integrate into the
genome of basal layer cells. The integration disrupts the viral genome resulting in
increased expression of the viral oncogenes and stabilization of their oncoproteins
which drive transformational changes in the host cell [17-19]. Sometimes, the
presence of episomal genome in the same cell that has an integrated viral genome
enhances the expression of the integrated genome which could further push
forward the transformational potential [20]. Although the productive life cycle of the
virus prefers an infection of a multilayered differentiated epithelium, HPVassociated cancerous lesions are usually seen in areas with an atypical
organization that are more vulnerable to transformation changes. Examples of

Figure 1.1: The HPV life cycle. The model on the left represents the productive
life cycle of HPV. Infection occurs through microabrasions in the epithelium to the
basal layer cells. Then, through timed and leveled gene expression switching
among the viral genes, a new progeny of viruses will be formed that sheds from
the apical layer. The picture on the right side shows the stages of HPV-induced
malignant transformation. There is no productive pattern, but oncogenes
expression throughout the epithelium with resultant dysplasia/invasive carcinoma.
Figure reproduced from Thomas et al, Oncogene 2008, 27, 7020 [16].
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these regions are the transitional zone of the cervix; the dentate line of the anus
where the squamous and columnar epithelia meet; and the reticulated epithelium
in of the palatine tonsillar crypts [21-23]. However, HPV HR types can cause
cancer in other sites like the endocervix proper, nasopharynx, larynx, and others.
1.3 HPV clearance and persistence:
There are more data collected concerning cervical cancer if compared to
other HPV-associated cancers. Most infections occur around the time of puberty
and the start of the sexual life though infection could happen anytime later in life
[Reviewed in 24]. This could be linked to the hormonal changes and the
endocervical epithelial damage caused by exposure to the acidic vaginal
secretions.

Figure 1.2: The natural history of cervical cancer. Schematic representation of
HPV-positive cancer as an example of HPV-associated cancers. Most of the cases
undergo clearance within the first 2 years. Persistent infection may progress to
low-grade dysplasia where the majority of the cases may regress. When the
dysplasia develops into high grade, it is more likely to progress to invasive cancer.
Figure reproduced from Pagliusi et al Vaccine 23 (2004) p572 [38].

4

The lifetime risk of getting infected is 80-90% [25]. About 90% of the HPV
infections are asymptomatic transient infections that will clear spontaneously
within a period of 2 years from the time of acquisition [26,27]. The remaining 10%
will continue as a persistent infection that may develop into low- grade dysplasia.
80% of low-grade dysplasia will regress spontaneously and resolve and the
remaining percentage will proceed into high-grade dysplasia [25]. Again, although
high-grade dysplasia is considered a pre-cancerous condition, only less than a half
of the high-grade dysplasia cases may develop into cervical cancer over a total
period of 5-30 years from the time of infection [28-30].
The overall risk of developing cervical cancer from an HPV HR infection is
only 0.3-1.2% [31]. At any given time, 12% of all women are HPV-infected with a
much higher percentage in young age [32] (figure 1.2). Risk of HPV infection/
cancer development can be reduced by prophylactic vaccination, personal
hygiene, male circumcision, and better awareness [33,34]. On the other hand,
immunodeficiency, smoking, oral contraceptive use, and chlamydial infections may
increase the risk [31, 35-37].
1.4 The HPV genome and its products:
The HPV genome is divided into 3 functional regions: the Upstream
Regulatory Region (URR), also known as Long Coding Region (LCR) (1 kb in size);
and 2 coding regions designated as Early (4 kb) and Late (3 kb) which contain the
Open Reading Frames (ORF) [39,40]. The URR contains the sequences that
regulate the ORF gene expression. It contains the early promoter which in HPV16
is located at p97, while the late promoter is contained within the E7 ORF sequence
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at p670 [41]. The Early (E) and Late (L) genes have been numbered according to
the size of the ORF with number 1 referring to the largest one [40]. HPV encodes
6 Early and 2 Late gene products. E1 has a DNA helicase activity, and along with
E2, it plays an important role in viral genome replication. Additionally, E2 regulates
transcription of other genes. E2 represses E6/E7 gene transcription and a release
of this repression occurs during integration that disrupts E2 yielding to the
transformational potential of the virus [3,18,42]. Actually, E2 can cause
senescence in HPV-positive cancer cells if it is re-introduced into cells with only
integrated viral genome [43]. There is no E3 in the HPV16 genome.

Figure 1.3: The HPV 16 genome. The HPV16 genome can be considered a
typical example of an HPV genome. It consists of early and late regions and the
URR. E1 and E2 are involved in viral replication and transcription. E2 also plays a
role in regulating transcription of the early genes, mostly inhibitory action. E6 and
E7 are oncogenes and play other roles in the normal viral life cycle. The late region
encodes for L1 and L2 proteins which are respectively the major and minor capsid
proteins. The Upstream regulatory region (URR) contains promoter and enhancer
elements and the origin of replication Figure reproduced from Stanley M, Clinical
Microbiology Reviews Apr 2012, 25 (2) 216; DOI: 10.1128/CMR. 05028-11 [81].
6

The E4 protein disintegrates the cellular cytoskeleton to release the virus
from infected cells [44] (Figure 1.3). The E4 sequence varies considerably among
different papillomaviruses which is thought to be involved in viral tropism [45]. E5
protein augments the proliferative action of E6/E7 protein with a possible role in
driving the malignant transformation [46]. However, some resources say that E5
sequence is often deleted during integration which may mean that E5 is not
important in late-stage carcinogenesis [47].
The E6 and E7 oncoproteins have a long list of actions that are important in
the context of HPV-mediated transformation. E6 and E7 are small proteins of 21
and 17 kDa, respectively [48,49]. The hallmark action of E6 is its interference with
the tumor suppressor protein p53 with a subsequent abrogation of apoptosis;
release of cell-cycle arrest; and accumulation of DNA damage [50]. E6 can
ubiquitinate and degrade p53 with the help of E6-associated protein and E3ubiquitin ligase [51]. E6 can also export p53 from the nucleus or disrupt its nuclear
localization signal, making it unavailable to exert its role [52]. Moreover, E6
manipulates the p53-DNA binding sites to decrease p53 transcriptional activity
[53,54]. However, not all of the p53 is degraded in an E6-expressing cell [55-58]
Our lab has also shown that p53 level still increases in response to UV radiation
of HPV16 transformed cells [59]. Furthermore, E6 promotes proliferation and
immortalization by enhancing the transcription of telomerase reverse transcriptase
(hTERT) which adds hexamer repeats to the telomeric ends of the chromosomes
[49, 60]. This action in addition to E7 role on Retinoblastoma protein allows for an
unlimited proliferative potential of the HPV HR infected cells [61,62]. E6 can induce
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chromosomal abnormalities through inactivation and degradation of human
minichromosome maintenance 7 (hMCM7) whose function is to prevent more than
one round of DNA replication during a single cycle [63,64]. Loss of p53 will result
in loss of the G1 and G2 checkpoints that result in chromosomal aneuploidy driven
by continuous proliferation [65] (figure 1.4).
On the other hand, the E7 protein has another set of interactions. The
hallmark role of E7 is inactivation and degradation of the tumor suppressor
retinoblastoma protein (Rb) and its family members p105, p107 and p130 [66]. E7
has no DNA binding capacity, but it phosphorylates/inactivates Rb releasing the
transcriptional factor E2F that will enter the nucleus to mediate E7 proliferative
functions and drive the cell cycle [67-69]. Additionally, E7 suppresses the activity
of p21/p27 releasing CDK2 and stabilizes it, which also drives the G1-S phase of
the cell cycle [70,71]. E7 contributes to genomic instability by enhancing centrioles
amplification and chromosomal aneuploidy resulting in further accumulation of
genetic damage [72]. These DNA damages and stress stimuli would activate p53;
however, E6 shuts down this effect by keeping p53 levels low and by inhibiting p53
activity [73-75]. HR E7 also has a telomere lengthening activity that further
contributes to the immortalization potential [76] (figure 1.4).
E7 alone has some transforming capacity while E6 doesn’t have it when it
is alone; however, when they are together, their effects are synergistic [77]. In an
experiment to show the effect of E6, E7 and both E6/E7 in transgenic mice model,
E6 transgenic mice exhibited tongue and esophageal cancer at a very low rate. E7
and E6/7 transgenic mice developed cancer in 95% of the cases, but the E6/E7
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mice had high-grade carcinomas and multiple invasive lesions [78]. Despite their
widespread interactions, E6/E7 proteins are essential, but not sufficient for HPVassociated cancer development and require other events to promote their
transformational actions [78-80].
Lastly, the Late coding genes, L1 and L2, encodes for major and minor
capsid proteins [3]. Every viral coat consists of 360 L1 molecules arranged in
repetitive groups of 5 molecules called capsomeres [81]. All of E1, E2, L1, L2 are
well conserved among all papillomaviruses [3] (figure 1.3).

Figure 1.4: Molecular pathways affected by HPV-oncoproteins. This diagram
is applicable to all HPV-associated carcinogenesis. High-risk HPV E6 inhibits
apoptosis; deregulates proliferation and differentiation; and induces
immortalization. High-risk E7 enhances cellular proliferation by abrogating cell
cycle checkpoints and induces genomic instability. Both E6/E7 can inhibit tumor
suppressor genes, and drive transformation and carcinogenesis. Figure
reproduced from Gupta et al Journal of Biomedical Science (2019) 26:28
P11[83].
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1.5 HPV-associated cancers:
1.5.1 Head and neck cancer:
Head and neck cancers make up 3.5% of all cancers in the United States
and Europe [84], and the 6th most common cancer worldwide [85], with a global
annual incidence of 600,000 [86,87]. Tobacco smoking and alcohol consumption
are the 2 classical risk factors for head and neck squamous cell carcinoma
(HNSCC). In the last 30 years, there was an increasing trend for oropharyngeal
squamous cell carcinoma (OPSCC) with the discovery of HPV as an evolving risk
factor [88-90]. HPV association with head and neck cancers varies according to
the anatomical site with the highest contribution (90%) in the oropharynx (tonsillar
bed) [91-93]. Moreover, HPV16 prevalence in HPV-positive OPSCC is about 90%
followed by HPV18 (3%) [94,95].
There are marked differences between HPV-positive and HPV-negative
tumors in various aspects. Morphologically, HPV-positive cancers tend to be nondifferentiated non-keratinizing basaloid carcinoma [82,96,97], with regional lymph
nodes involvement [82,98]. In contrast with HPV negative tumors, HPV-positive
tumors occur more commonly in younger age patient with no history of smoking or
alcohol consumption [99,100]. There is no field cancerization in the tissues that
surround the HPV transformed lesion [82] which may be linked to the younger age
of the patients at the time of diagnosis that means less accumulation of mutations.
The HPV-positive patients have a better prognosis [98,101] that could be linked to
their younger age with less comorbidity; better immune reaction [102]; better
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sensitivity to chemo-radiotherapy [103]; and lower incidence of p53 mutations and
field cancerization [104].
Recently, our lab and others found that not all HPV-positive head and neck
cancers are expressing the HPV-oncogenes E6/E7. This group was designated as
HPV-inactive (HPV DNA + | E6/E7 mRNA -), to distinguish it from the HPV-active
(HPV DNA + | E6/E7 mRNA +); and HPV negative tumors (HPV DNA - | E6/E7
mRNA -) [105-107] (table 1.1). Interestingly, the gene expression profile varies
among these 3 cancer types. In HPV-active tumors, there is an increased
expression of genes involved in cell cycle progression, cell division, proliferation,
DNA replication, and DNA repair giving a picture of “proliferative profile”. In HPVnegative cancers, the genes that are involved in motility, migration, epithelialmesenchymal transition, and angiogenesis are usually overexpressed which give
an invasive and metastatic signature. Distinctly, HPV-inactive cancers vary from
the HPV-active ones and they have a gene expression profile that is close to, but
not identical, HPV-negative cancers [106] (figures 1.5, 1.6).
Table 1.1: Updated HPV-associated tumors classification.
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Figure 1.5: Gene ontology, HPV-active versus HPV-negative OPSCC
samples. The HPV-active tumors have a higher expression of genes involved in
the growth cell cycle, and mitosis “proliferative signature” (red bars). This signature
is absent in HPV-negative tumors, which are characterized by higher expression
of genes involved in cell motility, extracellular matrix, angiogenesis, and EMT (blue
bars) Reproduced from Tomar et al Head Neck. 2016 p18[106].

Figure 1.6: Gene ontology analysis of gene expression changes in HPVactive, -inactive and –negative tumors from European Americans (EA). HPVinactive tumors lack the "HPV signature" typical of HPV-active tumors, however,
they share many but not all the features of HPV-negative tumors, lacking changes
in a whole class of pathways including cell projections, leading edge, adherence
junctions. This finding suggests the gene expression signature of HPV-inactive
tumors is intermediate between that of HPV-active and HPV-negative Reproduced
from Tomar et al Head Neck. 2016 p18 [106].
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1.5.2 Cervical cancer:
HPV is responsible for almost all cases of cervical cancer [108]. Although
cervical cancer is a rare long term sequalae of HR HPV infection, it has a large
burden on human health. Despite the decreasing incidence in the developed
countries, it ranks the 2nd most common cancer in women world-wide due to the
lower surveillance and the higher incidence in the developing and low-income
countries [109]. The annual global incidence is over 500,000 with annual mortality
that exceeds 250,000 [109]. Similar to what we found in the head and neck
cancers, Banister et al have found that 8% of HPV-positive cervical cancers have
only the viral DNA with no E6/E7 transcripts (HPV-inactive) [110].

Figure 1.7: Difference between HPV-inactive and HPV-active in age at the
time of diagnosis (A) and survival (B). HPV-inactive cervical cancer patients
(solid blue) are 9 years older at the time of diagnosis and have a shorter survival
duration (6.4 years less) than HPV-active patients (dashed pink line) Figure
reproduced from Banister et al. Oncotarget, 2017, Vol. 8, (No. 8), pp: 13375-13386
[110].
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Also, there is an obvious discrepancy in terms of clinical feature, gene
expression, mutations, and epigenetics. HPV-inactive cervical cancers occurred in
older

women

and

had

poorer

survival

(figure

1.7).

Morphologically,

adenocarcinomas and adenosquamous carcinomas were more common in the
HPV-inactive lesions. The HPV-active tumors showed higher expression of E2F
target genes, and increased AKT/mTOR pathway. Interestingly, the gene
expression profile of the HPV-inactive tumors revealed an increased expression of
WNT/β-catenin pathway. On the other hand, HPV-inactive tumors contained a
significant amount of somatic mutations compared to HPV active tumors especially
involving p53, WNT, and PI3K signaling [110].
1.6 Tumor suppressor p53:
p53 was the first identified tumor suppressor protein [111]. It is estimated
that 50% of tumors have loss-of-function mutations in p53 gene with the remaining
half has a certain level of p53 functional inactivation produced by viral proteins or
changes in the interacting pathways [111-113]. WT p53 is required for the
proposed action of chemotherapeutic drug and p53 mutation plays a role in
developing chemoresistance [114,115]. p53 is normally inactive and becomes
active when the cell is stressed or damaged. DNA damage, abnormal oncogenes
activity, or exposure to chemotherapeutic drugs and UV light are examples of
these stressful events [111]. p53 activation occurs by stabilizing the protein and
releasing it from MDM2 inhibitor either by modifying p53- binding site, or by
sequestering MDM2 and making it unavailable for p53 binding [116,117] (figure
1.8). This activation results in various downstream pathway interactions. It can

14

arrest the cell cycle by halting the G1-S and G2-M transitions by stimulating the
expression of p21 which is an inhibitor of cyclin-dependent kinases [118].
p53 plays an important role in the DNA repair mechanisms through the
induction of genes that are involved in nucleotide excision repair and chromosomal
recombination, hence, it protects the cell from the accumulation of genetic errors
and maintains the genetic stability [121,122]. If the damage is un-repairable, p53
will direct the cell into apoptosis through several mediators like Bax protein, a
prototype of pro-apoptotic proteins [123], or by stimulating the production of the
mitochondrial highly toxic reactive oxygen species [111]. Furthermore, p53 can
hinder tumorigenesis by stimulating the expression of genes that interfere with this
process [118, 124]. Therefore, we see in the HPV-negative and HPV-inactive
tumors where p53 is often mutated, the genes that are involved in angiogenesis
are over-expressed compared to that of HPV-active tumors where p53 mutation is
an infrequent event [106]. For all these actions, p53 was named the “guardian of
the genome” [119,120] (figure 1.8).
Most of the p53 mutations are missense mutations. They are usually
classified as conformational mutations that are most significant when the DNAbinding site is altered resulting in the inability of p53 to bind its target gene
promoters [125]. The deleterious effect of p53 mutations is not confined to the lossof-function, but also to gain-of-function effects. Mutant p53 may sequester other
tumor suppressor proteins including p53 itself, p63 and p73 which further
decreases the apoptotic capacity of the cell [126]. Moreover, the gain-of-function
property of mutant p53 causes the protein to acquire carcinogenic properties
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[127,128]. The important pathway in this context is its interaction with other
transcriptional factors including NF-κB, SMAD, Sp1, and others [129].
Consequently, loss of p53 function promotes cancer cell survival, tumor growth,
invasion, metastasis, and chemoresistance [130-132]. Additionally, mutant p53 is
highly stable due to the conformational change that renders it misfolded which
results in micro- and macro-inclusion bodies in the cells that could become toxic
to the cells when they aggregate because they resist proteasomal degradation
[133-136]. Targeting mutant p53 or its connections could be an important target
for anticancer therapy [129].

Figure 1.8: The p53 network. Stimuli like DNA breaks, oncogenes activation, and
UV exposure activate P53 either by modifying it or by inhibiting the MDM2 negative
regulator. P53 activation will result in widespread downstream interactions with
different pathways to induce growth arrest, apoptosis, or anti-angiogenic effect. As
negative feedback, p53 activation stimulate MDM2 gene which inhibits further
activation of p53 in the absence of additional stimuli. Figure reproduced from
Vogelstein et al. Nature 2000; Vol. 408 [111].
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1.7 HPV and DNA methylation:
Epigenetic modifications may serve as a key factor in cancer initiation and
progression [137,138]. In general, DNA methylation suppresses genes expression;
therefore, tumors usually have global hypomethylation with hypermethylation of
CpG islands of tumor suppressor gene promoters [139,140]. Higher methylation
profile in the genes of cell cycle and differentiation in the epithelial stem cell is
usually observed compared to the differentiated supra-basal cells [141].
Differential methylation processes occur in viral and cellular genomes [141].
Cervical cancer often has aberrant methylation leading to suppression of tumor
suppressors and activation of oncogenes [142]. As we mentioned earlier, E6/E7
expression is regulated by E2. E2 binding to E2-binding sites (E2BS) in the viral
URR regulates E6/E7 expression in a differential pattern. At low levels, E2 binds
to the high-affinity E2BS 1 with a subsequent increase in promoter activity and
E6/E7 expression. At higher levels, E2 binds the low-affinity E2BS 3 and 4
promoting the down-regulation of URR promoter activity and decreasing E6/E7
expression [143].
Although integration of the HPV genome disrupts E2 gene and releases the
inhibition of E6/E7 expression, methylation of the E2BS may substantially precede
this step [144,145]. According to the literature, methylation of the E2BS 1 results
in recruitment of transcriptional complex with increased promoter activity and
E6/E7 expression [146]. On the other hand, methylation of E2BS 3 and 4 inhibits
E2 binding, hence abrogating promoter inhibition and subsequently the E6/E7
expression will increase [143,147,148]. In other words, methylation will enhance
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HPV-oncogenes expression with suppression of the cellular tumor suppressor
genes by hypermethylation of their promoters [149]. However, our data show a
different story that may bring to light new pathways involved in the context of HPVinactive cancers. HPV-inactive lesions often have global DNA hypomethylation
with hypermethylation of promoter-associated CpG islands [110].
1.8 HPV and SIX1:
SIX1 is a DNA-specific transcriptional factor that belongs to SIX superfamily
of homeobox genes. SIX genes are master regulators of various downstream
pathways that are involved in embryogenesis and organogenesis [150-153].
Aberrant activity of SIX1 might cause tumorigenesis including cancers of breast,
cervix, ovary, liver, kidney as well as skeletal muscle [154-159]. SIX1 overexpression in malignant cells promotes cell proliferation, survival, and
invasiveness which lead to increased cancer aggressiveness, metastasis, and
poorer outcome [156,159-162]. Also, SIX1 can induce epithelial-mesenchymal
transition by down-regulation of the epithelial-related genes like E-cadherin and
upregulation of the mesenchymal markers like N-cadherin and vimentin [163,164].
This action is mediated through SIX1 influence on TGF-β, MAPK, WNT signaling
[165,166].
SIX1 strongly correlates with HPV E7. This relationship was tested in an in
vitro model of HPV16 transformed human keratinocytes (figure 1.9) [167,168]. The
model starts with primary human keratinocytes (HKc) that were transfected by
HPV16 DNA to produce early passage HPV16 transformed keratinocytes
(HKc/HPV16) that have a high proliferative capacity. Through selection in medium
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containing fetal bovine serum (5%) and high calcium (1 mM) these cells were
transformed into differentiation- resistant transformed human keratinocytes
(HKc/DR) which are not yet tumorigenic but have unlimited potential for
proliferation. SIX1 level increases as the cell passes from HKc to HKc/HPV16, then
to HKc/DR and HPV16 E7 levels increase as well. This is thought to occur because
HPV E7 inhibits Rb, releasing E2F which stimulate the expression of SIX1. When
SIX1 was over-expressed in HKc/HPV16, the cells were pushed to be HKc/DR
[169]. Interestingly, SIX1 over-expression in the HKc/DR stage of this cell line
drives the cells to become tumorigenic when they are injected into nude mice [166],
a similar effect to oncogenic Ras or Herpes simplex virus 2 (HSV2) transfection
[169-171].

Figure 1.9: In vitro model of HPV16 mediated transformation of human
keratinocytes. A schematic representation of our cell line development with the
related variation in HPV oncoproteins and SIX1 levels as well as the switching in
TGF-β signaling as cells progress through these steps.
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TGF-β signaling through the canonical/Smads pathway decrease Ski level
which is necessary to boost the activity of URR by its interaction with NF1. This, in
turn, will inhibit the URR activity, hence, it will inhibit E6/E7 expression. The
decrease in Ski level enhances the HKc/HPV16 sensitivity to the growth inhibitory
action of TGF-β [172]. SIX1 promotes the pro-tumorigenic function of TGF- β and
inhibits its anti-proliferative role [160]. SIX1 causes switch of TGF- β signaling from
the canonical pathway to the non-canonical pathway promoting E7 expression and
development of TGF- β insensitivity and EMT process [165,166,173].
1.9 Hypothesis and rationale:
Human papillomavirus is responsible for 5% of all human malignancies
[174]. HPV E6/E7 oncogene products are responsible for the transforming
potential of the virus through a series of molecular interactions. It is widely believed
that continuous E6/E7 expression in HPV-positive cancers is indispensable to
maintain the cancerous cell phenotype. Surprisingly, about 8% of HPV-positive
cervical cancer [110], and up to 30% of HPV-positive oropharyngeal squamous
cell carcinoma (OPSCC) are HPV-inactive [106] which means they don’t express
these oncogenes. As we have mentioned earlier, the gene expression profile of
the HPV-inactive cancers is different from the HPV-positive active tumors (which
are characterized by higher expression of the genes involved in cell proliferation)
and is similar, but not identical, to that of the HPV-negative tumors, (characterized
by higher expression of genes involved in cell motility, angiogenesis and EMT)
[106]. Interestingly, the HPV-positive primary OPSCC tumors tend to be HPVactive while recurrent or metastatic HPV-positive tumors in the same patients
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usually are HPV-inactive [105]. Contrary to the widely held belief that HPV
existence in the HPV-inactive tumors is merely a coincidental infection with no
influence on the carcinogenesis, we think that HPV-inactive tumors may arise from
HPV-active lesions that lose E7 expression during progression.
We hypothesize that HPV- inactive tumors start as HPV-active lesions,
then lose their dependence on the continuous expression of E6/E7
oncogene. This may be due to genetic and/or epigenetic modifications caused by
the genomic instability and the additional carcinogens to which the tumor is
exposed. Based on the finding that HPV-inactive cervical cancers often have
mutated p53 similar to HPV-negative while HPV-active tumors don’t [110], we
proposed that p53 mutation is a critical step for the development of HPV-inactive
lesions. Therefore, we investigated the effect of p53 mutation on HPV16 E7
expression. We knocked out the p53 gene in HPV16-transformed differentiationresistant human keratinocytes to simulate the loss-of-function mutation in the p53
gene. Due to the close positive bidirectional correlation between HPV E7 and SIX1
mentioned earlier, we checked the effect of SIX1 over-expression on the role of
p53 mutations in driving the conversion of HPV-active to HPV-inactive lesions.
1.10 Objectives:
First, to investigate the role of p53 mutation in suppressing HPV16 E7
expression, as a critical step in the development of HPV- inactive cancers from
HPV-active lesions. Second, to study the molecular mechanisms by which these
mutations can suppress E7 expression. Third, to determine the significance of
other mutations that may associate with the development of HPV-inactive tumors.

21

CHAPTER 2: MATERIALS AND METHODS
2.1 Cell culture:
Differentiation-resistant HPV16-transformed human keratinocytes (HKc/DR
cell line) generated in our laboratory in 1986-87 were used in our experiments
[167,168] (figure 1.9). The keratinocytes were harvested from human skin and
transfected with recombinant HPV16 DNA. The resulting HPV16-immortalized
human keratinocytes were cultivated in the differentiation-resistant (DR) medium
that consist of keratinocyte serum-free medium 1X (KSFM) (Life Technologies, cat.
17005042) supplemented with bovine pituitary extract (BPE); epidermal growth
factor 1-53 (EGF 1-53); calcium chloride to a final concentration of 1 mM; 5% fetal
bovine serum (FBS); penicillin 100 IU/ml; streptomycin 100 µg/ml; and gentamycin
5 µg/ml. Unlike their original primary cells, these cells exhibit differentiation
resistance and unlimited proliferative potential (figure 1.9). All the cells were grown
in 5% CO2, 37°C incubation conditions.
We also used the HKc/DR cells that were transfected with SIX1 overexpressing plasmid (HKc/DR-SIX1) to test the effect of SIX1 in our experiment for
the close link between SIX1 and HPV16 E7.
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2.2 CRISPR-Cas9 system:
The CRISPR-Cas9 system was used to knock-out the p53 gene in HKc/DR
and HKc/DR-SIX1 cells to mimic the p53 loss-of-function mutations that are highly
prevalent in HPV-inactive cancers. The CRISPR-Cas9 system was designed to
excise 186 bp from exon 2 of the p53 gene. Amplification of the CRISPR-Cas9 Up
and Down gRNA was done using KAPA SYBR FAST One-Step qRT-PCR
Universal (cat. KK4651), Amplifying HR, p53-CRISPR-Up and Down gRNA at final
concentrations of 1X, 2.5µM, and 1µg respectively in 20µl reaction volume. The
PCR products were purified using Agencourt DNAdvance kit (Beckman Coulter,
cat. A48705) according to the manufacturer protocol. Lipofectamine 3000 kit
(Invitrogen cat. L3000-008) was used for transfection according to the
manufacturer protocol. The cells were cultured in two 6-well plates; 1 plate was
transfected by CRISPR-Cas9 Up, CRISPR-Cas9 Down gRNAs of the Cas9 gene,
and Green Fluorescent Protein (GFP) to final quantities of 300ng, 300ng, and
1000ng, respectively per each well. The other plate was treated with only GFP
1000ng/well as a control.
2.3 Fluorescence-Activated Cell Sorting (FACS):
FACS for GFP signal was performed 48 hours after transfection by the
CRISPR-Cas9 reagents. After sorting, limited dilution of the cells (both CRISPRCas9/GFP treated and GFP-only treated) was achieved to get 1-2 cell/well of 96well plate. The cells were fed by DR medium and checked over 2 weeks to look
for the wells that gave a single colony growth pattern which indicates they have
emerged as a clonal proliferation of single cell to get a pure clone. When the
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selected wells became confluent, they were passaged into multiple 96-well
rounded bottom plate and BioRad PCR plates replica.
2.4 Characterization of the p53-KO and WT clones:
A. Resazurin viability assay:
To differentiate the wells that have p53 knocked-out (KO) clones from those
which still have wild-type (WT) p53, we treated one of the replica plates with nutlin
to a final concentration of 20µM and treated the control plate with DMSO. 4 days
later, the viability of the cells was assessed using Resazurin Viability Assay.
Resazurin sodium salt (Sigma R7017 CAS 62758-13-8 M.W. 251.18) was added
to both plates in a volume of 20µl/well for 4 hours at 37°C until the color started
changing from blue to pink. Fluorescence was measured at 560/590nm
wavelengths, and the ratio of the nutlin-treated plate reading to the DMSO-treated
plate reading was calculated for each well. Then the wells were sorted according
to the results into 3 groups: 1. those with a ratio of ≥0.8 were considered to be
mostly KO wells; 2. those with a ratio of ≤0.3 were considered to be mostly WT, 3.
the wells with a ratio whose ratios results were ˃0.3 and ˂0.8 were considered
equivocal.
B. Genomic DNA qPCR and gel electrophoresis:
KAPA SYBR FAST One-Step qRT-PCR Universal (cat. KK4651); p53-KOforward primer (5’-CTGGTAAGGACAAGGGTTGG-3’) and p53-KO-reverse primer
(5’-GCCAAAGGGTGAAGAGGAAT-3’); and genomic DNA were mixed to final
concentrations of 1X, 0.2µM,0.2µM, and 0.5ng/ul, respectively, per 20µl reaction.
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This was followed by DNA gel electrophoresis to compare the PCR product size
against p53-KO and p53-WT positive controls. Only the wells that gave a single
band at the 309 bp or 495 bp length were chosen as p53-KO and WT cell lines
which matched the p53-KO and p53-WT positive controls, respectively (figure2.1).

Figure 2.1: Gel electrophoresis of p53 KO/WT qPCR products. Only the
samples that gave a single band corresponding to one of the controls was chosen
as p53-KO or p53-WT accordingly.

Figure 2.2: Sanger sequencing data. As we can see here, our p53-KO lines are
missing the yellow segment that is seen in the p53 genetic map and p53-WT
sequences. The deletion corresponds to the intended region to be deleted by
CRISPR gRNA design. The red labeled bases are the joining ends.
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C. Sanger sequencing:
Sanger sequencing was done to further confirm the success of the CRISPRCas9 in deleting p53 and to check for the stability of the deletion after about 50
passage number. Using the same qPCR reagents and conditions mentioned
above, p53 gene across the deleted segment was amplified for p53-KO and p53WT lines. Then the qPCR products were analyzed by Sanger sequencing (Eton
Bioscience Inc.) to confirm the deletion happened in the same intended region of
exon 2. The results were compared to NCBI p53 gene sequence data (figure 2.2).
2.5 DNA/RNA isolation:
Qiagen AllPrep DNA/RNA mini kit (cat. 80208) was used to extract RNA
and DNA from the cell pellets following the manufacturer protocol. The
concentration and purity were measured by Implen Nanodrop Pearl.
2.6 cDNA synthesis:
Bio-Rad iScript cDNA Synthesis kit (cat. 1708891), and Bio-Rad iCycler
thermal machine were used to make complementary DNA (cDNA) from the RNA
template isolated from the cells. 4 µl 5x iScript reaction mix, 1 µl iScript reverse
transcriptase, 750ng RNA template, and RNase free water were mixed to a total
volume of 20 µl/reaction and converted using the Bio-Rad provided protocol.
2.7 cDNA quantification:
For accurate quantification of the cDNA concentration after reverse
transcription, cDNA was hydrolyzed in an aliquot of each reaction by mixing 7 µl
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cDNA with 2.1 µl NaOH (1M) and 1.8 µl EDTA (0.25M). The mixture was incubated
in the thermal cycler at 70°C for 15 min. Then, 3.5 µl HEPES (2M) was added to
it. Quanti-iT OliGreen ssDNA kit (cat. 011492) was used following the supplied
protocol. A fluorescence microplate reader was used to measure the fluorescence
at 480nm excitation/520nm emission.
2.8 Real-time qPCR:
BioRad iQ SybrGreen Super Mix was used to relatively quantify HPV16 E7
mRNA level in reference to B-actin as an internal control. Primers used are HPV16
E7 Forward (5’-CCGGACAGAGCCCATTACAAT-3’), HPV16 E7 Reverse (5’ACGTGTGTGCTTTGTACGCAC-3’).
2.9 Spheroid assay:
The cells were grown as spheroid to be analyzed later by RNAscope. The
bottom of 100 mm tissue-culture plates was covered by 5ml of 0.5% agarose
cushion prepared by making 1:10 dilution of 5% agarose gel mixture in DR
medium.

Figure 2.3: Schematic representation of the spheroid assay. Cells were grown
on agarose cushion to form a 3-dimensional-spheroids.
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The cells formed floating spheroids rather than adhering colonies. After 3-4
days, the spheroids’ diameters were measured using Lumenera Infinity1 Software
and when they exceeded 200µm, spheroids were collected for further examination
(figure 2.3).
2.10 Paraffin-Embedded Spheroid Block Formation:
After collection, the cellular spheroids were fixed overnight in 1.5ml
Eppendorf tube containing 1ml of 2% paraformaldehyde (PFA). Then, a
dehydration step followed by replacing the fixative using a gradually increased
ethanol concentration (70,80,95,95, 100 and 100% 15 min each). Using a
micropipette, the spheroids were transferred to embedding molds filled with xylene
for 10 min. The xylene was replaced by molten paraffin. The blocks incubated
overnight at 56°C then -4°C before sectioning. Some of the sections were stained
by Hematoxylin and Eosin stain and others by RNAscope in situ hybridization for
HPV16 E6/E7 mRNA.
2.11 Preparing chamber slides with adherent cells:
Cells were seeded on chamber slides Nunc Lab Tek II (Thermo Scientific,
cat. 154534PK). When they became about 80% confluent, they were washed in
1%PBS and fixed in 2-4% PFA for 30 min. Then a series of washing in 1%PBS
with dehydration by imersing them in a gradually increased concentration of
ethanol and rehydration again. Pretreatment with hydrogen peroxide and protease
III followed it to be ready for ISH.
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2.12 HPV16 E6/E7 mRNA in situ hybridization (RNAscope):
HPV16/18 E6/E7 mRNA in situ hybridization (ACDBio RNAscope 2.5 HD
Reagent Kit-Brown cat. 322300; ACDBio RNAscope probe HPV16/18 cat.311121)
to visualize the HPV16 E6/E7 mRNA expression in sections of the p53-KO and
p53- WT HKc/DR derived spheroids. Although the probe can detect both HPV16
and 18, our cells contain only HPV16 genome and so any signal will pertain to it.
2 positive controls were used: RNAscope Hs-PPIB probe (ACDBio cat. 313901)
applied to our cell of interest, and HPV16/18 E6/E7 probe applied to CRISPRuntreated HKc/DR cells. 2 negative controls: RNAscope DapB probe (ACD Bio cat.
310043) applied to our transformed cells, and same target probe HPV16/18 E6/E7
applied to normal human keratinocyte taken from newborn foreskin.
These cells were grown on chamber slides using the manufacturer protocol
to fix and pretreat cultured adherent cells for single-plex 2.5 Chromogenic assay.
Spheroids slides were pretreated using FFPE Sample Preparation and
Pretreatment manual for the RNAscope 2.5 Assay Part1 Document No.322452.
Then both the adherent cell slides and the cellular spheroid slides were stained
using the manufacturer protocol for RNAscope 2.5 HD Detection Reagent-Brown
User Manual Part 2 Document number 322310-USM.
2.13 DNA demethylation treatment:
5-Aza-2′-deoxycytidine (Sigma-Aldrich, cat. A3656) was dissolved in
DMSO. Three different final concentrations were used (5,10 and 20 µM) to validate
the therapeutic effect against its toxic effect. We used DMSO treatment as a
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control. Fresh medium with either treatment was added at 0, 24, 48 hours and the
cells were collected at 72 hours to be analyzed by Real-time qPCR for HPV16 E7
expression.
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CHAPTER 3: RESULTS
We were able to isolate and grow 2 lines of each of p53-KO and p53-WT
HPV16-transformed differentiation-resistant human keratinocytes (HKc/DR). At
early passage number (˂5), HPV16 E7 mRNA levels in the p53-KO cells
decreased by 25-50% from that of p53-WT control (figure 3.1). Since we had
previously observed that E7 level increases with increasing passage number in
HKc/DR cells, we accelerated the process by culturing only 5000 cells in 100 mm
cell-culture plates and kept passaging them when confluent. After 10 through 14
such passages, we collected cells, extracted RNA, and ran the RT-qPCR again for
HPV16 E7. We noticed an increase in the level of E7 mRNA in both the p53-KO
and WT lines. However, the expression was significantly lower in the p53-KO lines
and the gap between the p53-KO and WT lines got increased with increasing the
passage number (figure 3.2). This indicates that there is inhibition of the HPV16
E7 expression associated with knocking out p53 gene.

HPV16 E7 mRNA
level

1.60
1.40
1.20
1.00
0.80
0.60
0.40
0.20
0.00

P >0.05

KO

WT

Figure 3.1: RT-qPCR HPV16 E7 of p53-KO and WT HKc/DR at early passage
number. At low passage number (P<5), E7 mRNA in the p53-KO HKc/DR is lower
than its level in the WT counterpart but the difference is not significant.
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Figure 3.2: RT-qPCR of p53-KO and WT HKc/DR cells at passage number (1014). At passage number 10 through 14, E7 expression is significantly lower in the
p53-KO lines compare to their WT counterpart.

To explain the mechanism of inhibition of E7 expression in cells with
p53KO, we postulated an epigenetic modification could have happened to the p53KO HKc/DR cells. Therefore, we treated the cells with 5-Aza-2’- deoxycytidine, a
DNA demethylating agent. We found that E7 expression in the p53-KO HKc/DR
cells increases with increasing concentrations of 5-Aza-2’- deoxycytidine from 5 to
10 to 20 µM final concentration in the growth medium (figure 3.3). We compared
the E7 expression results to that of DMSO-treated p53-KO HKc/DR cells as a
negative control and all were compared to p53-WT lines at the same passage
number to exclude variability error that could happen when comparing different
samples at different passage number of cell growth. We noticed that the level of
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Figure 3.3: Reversal of E7 expression upon DNA demethylation. HPV16 E7
mRNA inhibition in p53-KO HKc/DR cells is reversed after 5-aza-2’ deoxycytidine
treatment in a dose-dependent pattern compared to DMSO treated p53-KO cell
and p53-WT line.
E7 mRNA is directly related to the dose of 5-Aza-2’- deoxycytidine and the
expression level of E7 in the 20 µM-treated cells is approaching the E7 level of the
p53-WT. This means that a methylation process is affecting the HPV16 genome,
inhibiting expression of the E7 gene.
RNAscope HPV16 E6/E7 in situ hybridization data obtained from p53-KO
and WT cellular spheroids were confirmatory and explanatory to the RT-qPCR
results. We found that in the p53-KO lines, some spheroids completely lost their
HPV16 E6/E7 mRNA while others have a mixed pattern (figure 3.4). This finding
suggests that loss of E7 expression occurs in clones of cells, not in the entire
population of p53-KO cells. We didn’t see this variability in the p53-WT lines which
exhibit a uniform distribution of HPV16 E7 mRNA throughout the spheroids. This
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finding confirms that there is an inhibition of E7 expression, but it is a relative rather
than an absolute suppression due to a heterogeneous population of cells.
Similarly, minimal and “patchy” E7 expression was noticed in p53-KO and
HKc/DR cells that were grown adherent on glass slides, in contrast with the robust
and almost ubiquitous signal detected in p53-WT HKc/DR (figure 3.5).

Figure 3.4: HPV16 E6/E7 mRNA in situ hybridization of spheroid grown p53KO/WT HKc/DR cells. In the p53-KO lines (A) (B), some spheroids are completely
lacking E6/E7 mRNA while others have a partial to total distribution of oncogenes
mRNA.In the p53-WT lines, (C)(D) there is a uniform distribution of E6/E7
expression in all cellular spheroids.
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Figure 3.5: HPV16 E6/E7 mRNA in situ hybridization of adherent p53-KO/WT
HKc/DR cells. All cells are grown as 2D adherent culture. (A) p53-WT cells show
robust E6/E7 mRNA expression. (B) p53-KO cells have minimal E6/E7 expression.
(C) RNAscope supplied positive control Hs PPIB. (D) RNAscope supplied negative
control DapB

Morphologically, we found 2 different patterns of cell growth in both the p53KO and WT lines cultured at very low density to allow for the formation of
monoclonal colonies (figure 3.6). A dispersed morphology, where the cells exhibit
a sparsely scattered pattern that gives the colonies a satellite shape, and the
coherent pattern, where the cell group together in a tight pattern forming round or
oval colonies. We determined the number of colonies of each pattern in each line
after fixing the cells in methanol and stained with Gentian violet. We found that
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dispersed colonies are more common in the p53-KO lines than in the WT lines.
The ratio of the average percentage was KO:WT; 70%:30%. Cells in dispersed

Figure 3.6: Dispersed and coherent colony pattern. (A) Dispersed colony
pattern (B) Coherent colony pattern (C),(D),(E) and (F) HPV16 E7 mRNA in situ
hybridization in the p53-KO dispersed; p53-KO coherent; p53-WT dispersed; and
p53-WT coherent, respectively.
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colonies are more likely to have a spindle morphology rather than the usual ovoidpolygonal shape.
To investigate the status of HPV16 E7 expression in each colony pattern,
we isolated these phenotypes by growing the cells in a limited dilution to get 1
cell/well of 96 well plates. After observing the pattern of their growth, we were able
to get clonal proliferation for each colony pattern and p53 knock out status.
However, the RT-qPCR results showed that the E7 expression was not markedly
different between the p53-KO and WT lines in relation to colony pattern (data not
shown). We also ran an HPV16 E6/E7 in situ hybridization for these colonies, but
there was no significant variation in E7 mRNA distribution (figure 3.6).
Because of the close link between E7 and SIX1, we tested the effect of SIX1
over-expression on the observed difference in E7 expression between p53-KO and
WT lines. We tested the effect by knocking out p53 in HKc/DR cells that were
transfected with a SIX1 expressing plasmid [164]. We found that SIX1 overexpression prevents inhibition of E7 expression in p53-KO HKc/DR-SIX1
compared to p53-WT HKc/DR-SIX1 (figure 3.7).
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Figure 3.7: Effect of SIX1 overexpression on E7 expression in p53-KO cells.
Exogenous SIX1 over-expression in the HKc/DR cells prevents inhibition of HPV16
E7 expression in response to p53-mutation.both in early passage (A) and passage
number 10 (B)
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CHAPTER 4: DISCUSSION
4.1 Conclusion:
Loss-of-function mutations in the p53 gene set the stage for the loss of
continuous expression of HPV oncogenes in HPV16-transformed cells. When we
link this research outcome with the published data about the high frequency of p53
mutations in HPV-inactive cancers, we can conclude that p53 could be a driver in
the shifting process of HPV active to inactive lesions. Even though p53 activity is
already at a minimum in the HPV-driven tumors due to its inhibition by HPV E6, its
mutation has a more potent action. p53 inhibition is dynamic in the HPVtransformed cells and still can respond to stressing events like UV radiation [59].
Loss of p53 alone may not be sufficient, per se, to induce loss of E7 expression,
but it is a necessary step.
We had difficulty in isolating cells or spheroids that are completely lacking
the E7 signal for further genetic and epigenetic analysis to investigate other
pathways that are affected by knocking out p53 in our cells.
We also ascertained that loss of E7 expression may be due, at least in part,
to DNA methylation as we have noticed an increase in E7 expression upon
demethylating the DNA with 5-aza-2’-deoxycytidine. However, a more in-depth
methylation study is needed to determine the exact locations that are
distinguishably different in their methylation profile between p53-KO and WT lines
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and the possible mechanism underlying these changes. These results appear to
contradict what we mentioned earlier, that methylation of the HPV genome
enhances its oncogenes expression [143,146-149]. However, this discrepancy
may highlight the importance of methylation of specific targets in controlling or
modulating HPV oncogenes expression. Nevertheless, we still hypothesize that
methylation of the HPV16 URR, which contains the sequences that control E6/E7
expression, is part of the mechanism by which cells with deleted p53 silence E7.
The finding that p53-KO HKc/DR cells are more likely to have a dispersed
pattern of colony growth and a spindle-shaped morphology suggests that these
cells are more likely to have an EMT and cell motility signature. EMT and motility
signature is characteristic of HPV-inactive and HPV-negative tumors. Therefore,
we may have already driven the HPV16-transformed cells to become independent
of the expression of HPV oncogenes by knocking out p53. However, the cells need
to be further studied for markers of EMT and gene expression profiles to confirm
what we are hypothesizing.
The role of SIX1 in the mechanisms by which HKc/DR-SIX1 become
independent of E7 also deserves additional studies, as it was intriguing to find that
in HKc/DR cells that overexpress exogenous SIX1, p53-KO does not result in loss
of E7 expression.
4.2 Significance:
This project expanded our understanding of the molecular mechanisms that
HPV can use to transform infected normal cells into cancerous cells, whether or
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not its oncogenes are expressed. HPV-positive OPSCC is more responsive to
chemo-radiation therapy [103]. However, sometime chemo-radiotherapy sensitive
patients turn to be resistant to it, similar to HPV-negative patients. This can be
explained as being due to the emergence of a subpopulation of HPV-inactive tumor
cells that have similar characteristics to HPV-negative cancers which are resistant
to this treatment modalities. If this is the case, then it would be advisable to check
for HPV activity status and not only HPV DNA positivity in these cancers prior to
initiating standard antiproliferative therapies.
A better knowledge of the mechanisms by which HPV-inactive cancers arise
is also useful in the context of therapeutic vaccines targeting HPV products. Most
of the vaccines currently under investigation use the E7 protein as a target [175].
However, as we have seen, a considerable percentage of HPV-positive cervical
cancer and OPSCC is HPV-inactive which means there are no E6/E7 proteins.
Hence, these vaccines will be ineffective in eliminating HPV-inactive lesions and
may even select for HPV-inactive clones in the tumor cell population. This issue
should be considered when testing the effectiveness of the vaccine to avoid false
negative results. Also, these results mandate the development of therapeutic
vaccines that use a different route of interactions to eliminate HPV-inactive tumors.
Last, but not least, if HPV plays a role in the pathogenesis of HPV- inactive
cancers, HPV prophylactic vaccines will have a wider range of protection
especially in head and neck cancer where the percentage of HPV-inactive tumors
is relatively higher and vaccination is not yet routine for males [176].
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4.3 Future work:
It is important to get a pure population of p53-KO lines that have no E7
expression for further analysis. We need to study the methylation status of the p53KO lines and to compare it to p53-WT lines. Genetic analysis and gene expression
analysis will be highly valuable in detecting other possible mutations and or
changes at the level of gene expression.
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